Page 51 - EndoProxy2012_final

endo | 100 Endo Boulevard | Chadds Ford, Pennsylvania 19317 45
the sole or the shared power of disposition or the power to vote. His beneficial ownership excludes (i) options to
purchase 6,642 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and 2010
Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares of unvested re-
stricted stock units.
(f) Mr. Montague is a director of Endo. The business address for Mr. Montague is 9695 Rocky Point, Clarence, NY
14031. Mr. Montague’s beneficial ownership represents (i) options to purchase 11,836 shares of common stock
granted under the Endo Pharmaceuticals Holdings Inc. 2007 Stock Incentive Plans which will be exercisable within
the next 60 days and (ii) 15,397 directly owned shares of common stock. His beneficial ownership excludes (i) op-
tions to purchase 6,642 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2007 and
2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares of unvested
restricted stock units.
(g) Dr. Nash is a director of Endo. The business address for Dr. Nash is c/o Jefferson School of Population Health, 1015
Walnut Street, Suite 115, Philadelphia, Pennsylvania 19107. Given his March 2011 appointment to the Company’s
Board, Dr. Nash has no beneficial ownership in the Company as of April 9, 2012. However, he has been granted
5,481 restricted stock units, none of which has vested as of April 9, 2012.
(h) Mr. Scodari is a director of Endo. Mr. Scodari’s beneficial ownership represents (i) options to purchase 15,715
shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 and 2007 Stock Incentive
Plans which will be exercisable within the next 60 days and (ii) 23,329 directly owned shares of common stock.
His beneficial ownership excludes (i) options to purchase 7,934 shares of common stock granted under the Endo
Pharmaceuticals Holdings Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next
60 days and (ii) 5,481 shares of unvested restricted stock units.
(i) Mr. Spengler is a director of Endo. The business address for Mr. Spengler is 616 Orchid Avenue, Corona del Mar,
CA 92625. Mr. Spengler’s beneficial ownership represents (i) options to purchase 15,715 shares of common stock
granted under the Endo Pharmaceuticals Holdings Inc. 2004 and 2007 Stock Incentive Plans which will be exer-
cisable within the next 60 days and (ii) 22,955 directly owned shares of common stock. His beneficial ownership
excludes (i) options to purchase 7,934 shares of common stock granted under the Endo Pharmaceuticals Holdings
Inc. 2007 and 2010 Stock Incentive Plans which will not be exercisable within the next 60 days and (ii) 5,481 shares
of unvested restricted stock units.
(j) Mr. Holveck is a director of Endo and is our President and Chief Executive Officer, effective April 1, 2008 and a
Director of the Company effective March 25, 2008. Mr. Holveck’s beneficial ownership represents (i) options to
purchase 600,605 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 and
2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii) 39,097 directly owned shares
of common stock. His beneficial ownership excludes (i) options to purchase 475,496 shares of common stock
granted under the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock Incentive Plans which will not
be exercisable within the next 60 days, (ii) 200,377 shares of unvested restricted stock units and (iii) 164,184 un-
vested, unearned performance share units.
(k) Mr. Levin is our Executive Vice President & Chief Financial Officer. Mr. Levin’s beneficial ownership represents (i)
options to purchase 76,326 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004
and 2007 Stock Incentive Plans which will be exercisable within the next 60 days, (ii) 4,977 directly owned shares
of common stock (iii) and 10,875 RSUs which will be converted to common stock within the next 60 days. His
beneficial ownership excludes (i) options to purchase 140,137 shares of common stock granted under his employ-
ment agreement and the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock Incentive Plans which
will not be exercisable within the next 60 days, (ii) 61,177 shares of unvested restricted stock units and (iii) 54,394
unvested, unearned performance share units.
(l) Ms. McHugh is our Chief Operating Officer. Ms. McHugh’s beneficial ownership represents options to purchase
72,422 shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004 Stock Incentive Plan
which will be exercisable within the next 60 days. Her beneficial ownership excludes (i) options to purchase 150,116
shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock In-
centive Plans which will not be exercisable within the next 60 days, (ii) 34,967 shares of unvested restricted stock
units and (iii) 31,883 invested, unearned performance share units.
(m) Dr. Gergel is our Executive Vice President, Research & Development & Chief Scientific Officer. Dr. Gergel’s benefi-
cial ownership represents options to purchase 69,233 shares of common stock granted under the Endo Pharma-
ceuticals Holdings Inc. 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days. His
beneficial ownership excludes (i) options to purchase 137,498 shares of common stock granted under the Endo
Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock Incentive Plans which will not be exercisable within
the next 60 days, (ii) 61,333 shares of unvested restricted stock units and (iii) 48,938 unvested, unearned perfor-
mance share units.
(n) Ms. Manogue is our Executive Vice President, Chief Legal Officer & Secretary. Ms. Manogue’s beneficial ownership
represents (i) options to purchase 388,669 shares of common stock granted under the Endo Pharmaceuticals
Holdings Inc. 2000, 2004 and 2007 Stock Incentive Plans which will be exercisable within the next 60 days and (ii)
30,835 directly owned shares of common stock. Her beneficial ownership excludes (i) options to purchase 109,632
shares of common stock granted under the Endo Pharmaceuticals Holdings Inc. 2004, 2007 and 2010 Stock In-
centive Plans which will not be exercisable within the next 60 days, (ii) 45,574 shares of unvested restricted stock
units and (iii) 37,709 unvested, unearned performance share units.